MTIP
ANIP icon

Magee Thomson Investment Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Magee Thomson Investment Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17
Closed -$1K – 98
2016
Q4 		$1K Hold
17
– – ﹤0.01% 40
2016
Q3 		$1K Buy
+17
New +$1.06K ﹤0.01% 36

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Magee Thomson Investment Partners's ANIP Position: Q1 2017 in Review

Magee Thomson Investment Partners sold out of ANI Pharmaceuticals (ANIP) in Q1 2017, closing a stake of 17 shares — an estimated $1K sold.

Magee Thomson Investment Partners first reported a position in ANIP in Q3 2016 and held it in 2 quarters. The position peaked at $1K in Q4 2016. 158 funds tracked by Wall St. Rank hold ANIP as of Q1 2017.

  • Magee Thomson Investment Partners reported no remaining ANI Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 17 ANI Pharmaceuticals shares in Q1 2017, an estimated $1K.
  • Magee Thomson Investment Partners first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • Magee Thomson Investment Partners's ANI Pharmaceuticals position peaked at $1K in Q4 2016.
  • 158 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2017.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2017, filed 21 Apr 2017.